AbCellera Biologics Inc.

Executive Summary

SELL, Low conviction. ABCL rates a SELL at Low conviction. The stock has rallied 76.9% in 3 months to $13.92, sits just 2.2% below its 52-week high, and now trades at 58.64x sales despite FY2025 revenue of $0.1B, down 30.1%, with deeply negative profitability. Near-term upside hinges on ABCL635 top-line Phase II data very soon, but at this price the setup looks asymmetric against investors if the data are mixed or if collaboration revenue remains weak.

Investment Thesis

The stock is trading on what AbCellera could become, not what the business currently is. That would be fine at a lower entry point, but $13.92 is not one. ABCL now sits only 2.2% below its 52-week high of $14.23 after a 76.9% move in the last three months and 141.3% above its 200-day average. Against that setup, the reported fundamentals are still thin: FY2025 revenue was $0.1B, down 30.1%, EPS was -$0.49, and operating margin was -1579.2%. This is not a stock priced on current cash generation. It is priced on a future pipeline and platform payoff that remains unproven.

That future now rests disproportionately on ABCL635. Management was explicit: "Based on this, we expect a top line data readout very soon." Execution on trial timing was better than expected, with enrollment and initial dosing completed in June, "well ahead of schedule." If the readout is clearly positive, the narrative can change fast because management also said, "If the data is positive, we believe ABCL635 will be highly derisked." But that is exactly why the risk-reward looks poor after the rally. Investors are paying up ahead of a binary event while the company has also disclosed scientific uncertainty around whether preoptic nucleus NK3R blockade is required for efficacy.

The balance sheet is the main reason this is not a high-conviction short-style SELL. AbCellera ended Q2 with $567M of cash and marketable securities, management cited over $675M available liquidity, and the CFO said the company has funding for "at least the next 3 years of pipeline investments." New Vertex and Jazz TCE deals added over $110M upfront cash, and Jazz includes 3 confirmed discovery programs plus 2 options. That validates the platform and limits financing risk near term.

The problem is that platform validation has not yet translated into stable operating performance. Q2 revenue fell to about $4M from about $17M a year earlier, net loss widened to about $55M, and EBITDA margin deteriorated to -1025.4% from -491.7% in Q1. Management also missed its timeline for moving another program into IND-enabling activities in H1, and ABCL575 will not be developed past Phase I. At this valuation, the market is paying for several successes before they are earned. The case for avoiding the stock depends on three things: ABCL635 is still binary, collaboration revenue remains volatile, and the current valuation leaves little room for anything short of a strong clinical win.

Key Metrics

Financial Strength

The balance sheet is the clean part of this story. Low leverage, a 12.77 current ratio, and $567M of cash and marketable securities give AbCellera time to fund internal programs without near-term dilution pressure, especially after over $110M of upfront cash from Vertex and Jazz. The issue is not solvency, it is burn efficiency. Revenue has become more volatile as collaboration mix shifted, while losses widened with heavier R&D spending, and Q2 EBITDA margin collapsing to -1025.4% shows the company is still far from operating leverage. This balance sheet can support strategy execution, but it does not by itself justify a premium sales multiple at the current share price.

Competitive Position

AbCellera's moat is its antibody discovery engine, data stack, and partner network, not a mature marketed product base. The recent TCE agreements with Vertex and Jazz are useful proof that counterparties still value the platform, and the Jazz structure with 3 confirmed programs plus 2 options suggests repeat business is possible. That said, the moat is only moderately durable because barriers in AI-enabled biologics discovery are rising across the industry, and platform value compounds only when it produces differentiated clinical assets or recurring economic participation. Today the platform is credible, but the evidence that it can consistently convert discovery capability into high-value downstream outcomes remains incomplete.

Management & Guidance

Management is giving investors a very clear near-term focus: ABCL635 top-line Phase II data very soon, ABCL575 readout in Q4 2026, and ABCL-688 plus ABCL386 into Phase I/II in 2027. Credibility is mixed rather than poor. The company executed well on ABCL635 enrollment timing and has beaten EPS estimates in 4 of the last 8 reported quarters, including a large beat in February 2026, but it also missed in the most recent quarter and acknowledged a missed H1 timeline for moving another program into IND-enabling work. Guidance on liquidity looks credible given the current cash position and partnership inflows, while guidance on value creation still depends on clinical outcomes more than on management promises.

Bull Case

• Liquidity is real: $567M cash and marketable securities at Q2 2026, with management citing over $675M available liquidity and runway for at least 3 years of pipeline investment.
• External validation improved: Vertex and Jazz TCE deals brought over $110M upfront cash, and the Jazz collaboration includes 3 confirmed discovery programs plus options for 2 more.
• Execution on ABCL635 trial timing was strong: management said enrollment and initial dosing were completed in June, well ahead of schedule, supporting a near-term readout.
• Innovation capacity is not the issue: quality sub-score for Innovation Investment is 100, and the pipeline still includes ABCL-688 and ABCL386 targeting Phase I/II starts in 2027.

Bear Case

• Revenue quality is weak: Q2 2026 revenue was about $4M, down from about $17M last year, driven by lower collaboration revenue and mix shifting toward research fees.
• Profitability deteriorated sharply: Q2 EBITDA was -$0.04B with margin -1025.4%, versus -491.7% in Q1, a 533.7 point sequential decline.
• The valuation already embeds a lot of good news: the stock is 141.3% above its 200-day average of $5.77 and only -2.2% below the $14.23 52-week high.
• Pipeline concentration is high: management explicitly said there are no plans to develop ABCL575 past Phase I, leaving ABCL635 as the key near-term value driver.

Valuation & Price Target

Engine price target $8.61 (-38.2% vs current), Low confidence.

• P/S Multiple: $3.58 (27% weight)
• Quality-adjusted: $15.37 (20% weight)

This call aligns with the quant baseline SELL (Low conviction) and the $8.61 price target, because the gap between current price and fundamentals is hard to ignore: 58.64x sales, FY2025 revenue down 30.1%, and operating margin -1579.2%. The quality-adjusted method points to $15.37, which explains why conviction is not high, since the balance sheet is strong and a positive ABCL635 readout could quickly change the earnings-power narrative. Sell-side consensus sits at Strong Buy (4 buy / 0 hold / 0 sell), but that is a low-signal data point here and looks more anchored to platform optionality than to current revenue quality and the stock's sharp rerating into a binary event.

Risk Assessment

Risk score 49/100 (Moderate). The biggest risk to a SELL is a clearly positive ABCL635 Phase II readout, because management says the asset would be "highly derisked" and the stock is already showing momentum with 76.9% gains in 3 months.

The Bottom Line

ABCL rates a SELL with Low conviction. The company has enough cash to keep building, real platform credibility with large partners, and a meaningful catalyst very near, but the stock already discounts too much of that future at 58.64x sales and near a 52-week high. This is not a call against the science long term, it is a call against the entry price ahead of a binary event while revenue and margins remain weak. A clearly positive ABCL635 readout that changes forward earnings power, or a sharp valuation reset closer to the $8.61 quant target, would be the main reasons to revisit the stance.